ESTRO meets Asia 2024 - Abstract Book

S215

Interdisciplinary – Lung

ESTRO meets Asia 2024

3. Barton, Michael, Susanna J, Shafiq J, Wong KJ, Delaney, Geoff. Estimating the demand for radiotherapy from

the evidence: A review of changes from 2003 to 2012. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2014 Mar 22;1–

5.

4. Tyldesley, Scott, Boyd C, Schulze K, Walker H, Mackillop WJ. Estimating the need for radiotherapy for lung

cancer: an evidence-based, epidemiologic approach. Int J Radiat Oncol. 2001;49(4):973–85.

5. Vinod SK. Lung cancer patterns of care in south western Sydney, Australia. Thorax. 2003 Aug 1;58(8):690–4.

6. Tyldesley S, Zhang-Salomons J, Groome PA, Zhou S, Schulze K, Paszat LF, et al. Association between age and the

utilization of radiotherapy in Ontario. Int J Radiat Oncol. 2000 May;47(2):469–80.

7. Khalifa J, Lerouge D, Le Péchoux C, Pourel N, Darréon J, Mornex F, et al. Radiotherapy for primary lung cancer.

Cancer/Radiothérapie. 2022 Feb;26(1–2):231–43.

8. Gondhowiardjo S, Christina N, Ganapati NPD, Hawariy S, Radityamurti F, Jayalie VF, et al. Five-Year Cancer

Epidemiology at the National Referral Hospital: Hospital-Based Cancer Registry Data in Indonesia. JCO Glob Oncol.

2021 Dec;(7):190–203.

352

Proffered Paper

Risk-adapted SABR for central/ultracentral primary lung cancer: safety/efficacy, and the role of PBT

Caroline Maguire, Amir Ameen, Crispin Hiley, Karim Keshwani, Christian Brunet, Vicki Spyris, Colin Baker, James M Wilson

Department of Oncology, University College London Hospital, London, United Kingdom

Purpose/Objective:

SABR for the treatment of central and ultracentral primary lung cancers is controversial because of concerns about excess toxicity. In medically inoperable patients with poor lung function, we treat with SABR, but allow PTV compromise to ensure that all organ at risk constraints (OARs) are met. We investigated the safety and efficacy of this approach and asked if PTV coverage could be improved with proton beam therapy (PBT).

Material/Methods:

Between December 2019-December 2023, 26 patients were treated with 60 Gy in 8 fractions or 50 Gy in 5 fractions for central or ultracentral lung cancer. PTV was compromised as necessary to meet mandatory dose constraints. Patients were followed up for toxicity and disease status. The 5 patients with the most PTV compromise were replanned with PBT.